Related scientific articles (all)

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

Authors : Nuciforo P, Townend J, Piccart-Gebhart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S
Year : 2023
Journal : Eur J Cancer
Volume : 181
Pages : 92-101

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.

Authors : Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Latocca MM, Arecco L, Pistilli B, Ruddy KJ, Ballestrero A, Del Mastro L, Peccatori FA, Partridge AH, Saura C, Untch M, Piccart-Gebhart M, Di Cosimo S, de Azambuja E, Demeestere I
Year : 2023
Journal : J Natl Compr Canc Netw
Volume : 21
Pages : 33-41.e16

Approaches to Fertility Preservation for Young Women With Breast Cancer.

Authors : Razeti MG, Soldato D, Arecco L, Levaggi A, Puglisi S, Solinas C, Agostinetto E, Spinaci S, Lapuchesky L, Genova C, Massarotti C, Lambertini M
Year : 2023
Journal : Clin Breast Cancer
Volume : 23
Pages : 241-248

Medical oncology education in Europe: equipping medical oncologists to provide the best care for patients with cancer.

Authors : Jordan K, de Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F
Year : 2023
Journal : Oncol Res Treat

Reply to S. Di Cosimo et al.

Authors : Agostinetto E, Venet D, Ignatiadis M, Kalashnikova E
Year : 2023
Journal : JCO Precis Oncol
Volume : 7
Pages : e2200644

Food in painting: From dietetics to symbolism.

Authors : Van Gossum A
Year : 2023
Journal : Clin Nutr ESPEN
Volume : 54
Pages : 374-381

Immunotherapy in breast cancer: an overview of current strategies and perspectives.

Authors : Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L
Year : 2023
Journal : NPJ Breast Cancer
Volume : 9
Pages : 7

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials.

Authors : Pala L, De Pas T, Pagan E, Sala I, Catania C, Zattarin E, Arnone P, Grassi MM, Colleoni M, Wolff AC, Cortes J, Piccart-Gebhart M, Gelber Rd, Viale G, Bagnardi V, Conforti F
Year : 2023
Journal : Breast
Volume : 69
Pages : 258-264

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

Authors : de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T
Year : 2023
Journal : ESMO Open
Volume : 8
Pages : 100772

ASO Visual Abstract: The Prognostic Value of Distinct Histological Growth Patterns of Colorectal Peritoneal Metastases-A Pilot Study.

Authors : El Asmar A, Demetter P, Fares F, Sclafani F, Hendlisz A, Donckier V, Vermeulen P, Liberale G
Year : 2023
Journal : Ann Surg Oncol

Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.

Authors : Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cortés J, OShaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart-Gebhart M
Year : 2023
Journal : Eur J Cancer
Volume : 178
Pages : 23-33

PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer.

Authors : Amato O, Buisseret L, Gebhart G, Plouznikoff N, Larsimont D, Awada A, Piccart M, Aftimos P
Year : 2023
Journal : Cold Spring Harb Mol Case Stud

CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.

Authors : Sallman DA, Kerre T, Havelange V, Poiré X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A, Alcantar-Orozco EM, Borissova R, Braun N, Dheur MS, Gilham DE, Lonez C, Lehmann FF, Flament A
Year : 2023
Journal : Lancet Haematol

Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions.

Authors : Castelo-Branco L, Morgan G, Prelaj A, Scheffler M, Canhão H, van Meerbeeck JP, Awada A
Year : 2023
Journal : ESMO Open
Volume : 8
Pages : 100764

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.

Authors : De Jaeghere EA, Tuyaerts S, Van Nuffel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, van de Vijver KK, Amant F, Vandecasteele K, Denys HG
Year : 2023
Journal : Cancer Immunol Immunother
Volume : 72
Pages : 475-491

Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials.

Authors : Perez-Gracia JL, Penel N, Calvo E, Awada A, Arkenau HT, Amaral T, Grünwald V, Sanmamed MF, Castelo-Branco L, Bodoky G, Lolkema MP, Di Nicola M, Casali P, Giuliani R, Pentheroudakis G
Year : 2023
Journal : Ann Oncol
Volume : 34
Pages : 70-77

Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy.

Authors : Jungels C, Pita JM, Costante G
Year : 2023
Journal : Curr Opin Oncol
Volume : 35
Pages : 1-9

ASO Visual Abstract: Prognostic Value of Preoperative Serological Biomarkers in Patients Undergoing Curative-Intent Cytoreductive Surgery for Colorectal Cancer Peritoneal Metastases.

Authors : El Asmar A, Delcourt M, Kamden L, Khaled C, Bohlok A, Moreau M, Sclafani F, Donckier V, Liberale G
Year : 2023
Journal : Ann Surg Oncol
Volume : 30
Pages : 1872-1873

ESPEN practical guideline: Home parenteral nutrition.

Authors : Pironi L, Boeykens K, Bozzetti F, Joly F, Klek S, Lal S, Lichota M, Mühlebach S, Van Gossum A, Wanten G, Wheatley C, Bischoff SC
Year : 2023
Journal : Clin Nutr
Volume : 42
Pages : 411-430

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.

Authors : Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA
Year : 2023
Journal : JAMA Oncol
Volume : 9
Pages : 29-39